General Psychiatry
June 21, 2023
Xiaofeng Lan, Chengyu Wang, Fan Zhang et al.
Background: Patients with anxious major depressive disorder (MDD) are more likely to have poorer outcomes than those with non-anxious MDD. However, the effect of esketamine on adolescents with anxious versus non-anxious MDD has remained unknown. Aims: We compared the efficacy of esketamine in adolescents with MDD and suicidal ideation, both anxious and non-anxious. Methods: Fifty-four...
The World Journal of Biological Psychiatry
June 20, 2023
Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Alina Wilkowska et al.
9 citations
OBJECTIVES: Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD. METHODS: This case presents a...
Frontiers in Psychiatry
June 20, 2023
Johannes T. Reckweg, Cees van Leeuwen, Cécile Henquet et al.
86 citations
Background Treatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in adult patients with TRD. Methods The Phase 1 part ( n = 8) of the trial investigated two single...
Behavioral Neuroscience
June 15, 2023
Caitlyn J Bartsch, Sophia Aaflaq, Jessica T. Jacobs et al.
Ketamine is a dissociative anesthetic that has been shown to have antidepressant effects in humans and has been proposed as a potential treatment for mood disorders such as PTSD and aggression. However, previous studies from our lab and others have demonstrated that ketamine’s effects are highly context- and dose-dependent. In a recent study, we found that 10 mg/kg ketamine could exacerbate the...
Frontiers in Neuroscience
June 12, 2023
Elena Argento, Egiroh Omene, Alexandra Jaeger et al.
10 citations
Functional seizures, a primary subtype of functional neurological disorder (FND), are a known cause of serious neurological disability with an increasing awareness of their impact amongst the neuroscience community. Situated at the intersection of neurology and psychiatry, FND is characterized by a range of alterations in motor, sensory or cognitive performance, such as abnormal movements, limb...
June 9, 2023
Mika Turkia
3 citations
preprint
This article presents the case of a young woman in her mid-twenties with a history of depression since childhood. She lived with a mother who failed to take care of her. The patient cared for the emotional needs of the mother instead of the mother caring for the daughter's needs. Her father was mostly absent. Already around the age of thirteen, the patient was severely depressed and was...
British Journal of Guidance & Counselling
June 8, 2023
Fuat Can Çalışkan, Sibel Akmehmet-Şekerler, Zeynep Kızıltepe et al.
ABSTRACT Along with anxiety and depression, mindfulness has recently gained attention among the predictors of college adjustment. This study conducted in Türkiye, investigated the relationship between mindfulness and college adjustment through the mediating role of depression and anxiety. Data were collected using the Depression Anxiety Stress Scale, the Mindful Attention Awareness Scale, and...
Bipolar Disorders
June 8, 2023
The authors have declared no conflict of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Journal of Education, Health and Sport
June 7, 2023
Paulina Czuchryta, Rafał Babiak, Karolina Bajak et al.
Introduction and purpose: The problem of major depression disorder (MDD) affects more and more people. In a few years, it may become the most common disease after cardiovascular diseases and cancer. MDD are manifested by a depressed mood, decreased energy, loss of interest and the ability to enjoy life, as well as a number of other additional symptoms. Untreated MDD can lead to disability. This...
Brain Sciences
June 4, 2023
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni et al.
46 citations
Bipolar depression remains a clinical challenge with a quarter of patients failing to respond to initial conventional treatments. Although ketamine has been extensively studied in unipolar depression, its role in bipolar disorder remains inconclusive. The aim of our scoping review was to comprehensively synthesize the current clinical literature around ketamine use in bipolar depression. A...
Frontiers in Psychiatry
June 2, 2023
Depression is among the most common mental health disorders worldwide and treatment resistant depression (TRD) represents a major challenge for both patients and clinicians. In recent years ketamine has received attention as an antidepressant agent, demonstrating promising results in TRD in adults. To date, few attempts have been made in treating adolescent TRD with ketamine and none have used...
International Journal of Surgery Global Health
June 2, 2023
Tooba Noor, Areej Shakil, Aimen Waqar Khan et al.
The COVID-19 pandemic has resulted in a surge in depression cases, a pervasive and debilitating mental illness1. This trend is evident in the increased prescriptions for antidepressants. Depression is a chronic condition that affects a significant proportion of the global population, with ~280 million people, or about 3.8%, suffering from it. As a result, it is a significant mental health...
Journal of Psychiatric and Mental Health Nursing
June 2023
Joanne Kraenzle Schneider, Saratu Garba Abdullahi, Scott D Easton et al.
WHAT IS KNOWN ON THE SUBJECT?: Researchers have examined several interventions for psychological distress, mindfulness being a popular one. One intervention that fosters mindfulness is mantram repetition. Mantram repetition is an ancient traditional practice of repeating a sacred word/phrase at various times throughout the day and whenever needed. Psychologically, mantram repetition can...
Cureus
June 2023
Tarika Nagi, Amit Jagtiani, Saurabh Somvanshi et al.
Intravenous ketamine infusions in subanesthetic doses have been shown to rapidly alleviate depressive symptoms. However, the efficacy of ketamine as an anesthetic during electroconvulsive therapy (ECT) for major depression has not yet been answered by a large randomized control trial (RCT). This scoping review aims to examine the available literature to determine whether the dose of ketamine...
Psychiatric Clinics of North America
June 2023
Anna Feeney, George I. Papakostas
Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistant depression. Intranasal esketamine has regulatory approval in the United States and European Union. Intravenous ketamine is often administered off-label as an antidepressant, though no standard operating procedures exist. Repeated administrations and the use of a...
Healthcare
June 1, 2023
E. Mousavi, Dena Sadeghi-Bahmani, Habibolah Khazaie et al.
Objectives: The aims of the present study were two-fold: to investigate whether, compared to an active control condition, a modified mindfulness-based stress reduction (MBSR) program could (1) reduce symptoms of stress and depression, and (2) regulate salivary cortisol and serum creatine kinase (CK) concentrations, two physiological stress markers. Methods: Thirty male wrestlers (Mage = 26.73...
Journal of Affective Disorders
June 1, 2023
Gustavo C. Leal, Breno Souza-Marques, Rodrigo P Mello et al.
Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine (esketamine), with the latter regarded as the main isomer for antidepressant effects. However, preclinical data and one open-label human trial suggest arketamine might exert a more potent and longer-lasting antidepressant effect with fewer side effects. We aimed to explore the feasibility of a randomized controlled...
Journal of Clinical Oncology
June 1, 2023
Manish Agrawal, Sarah Shnayder, Heather Honstein et al.
2 citations
12021 Background: Up to 25% of people living with cancer have depression. Existing psychological interventions have limited efficacy in treating depression. Psilocybin, a 5-hydroytrptamintergic psychedelic, coupled with group therapy is safe and effective in ameliorating symptoms of depression (Agrawal et al, ASCO 2022). Response to psilocybin treatment was observed in 83.3% of patients at 8...
Psychiatric Clinics of North America
June 1, 2023
Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan
32 citations
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also...
Frontiers in Cardiovascular Medicine
May 31, 2023
Kemei Wu, Miaomiao Wan, Huiqin Zhou et al.
ObjectiveTo investigate the clinical effects of mindfulness-based stress reduction (MBSR) intervention combined with early cardiac rehabilitation (CR) on patients with acute myocardial infarction (AMI) assisted with an intra-aortic balloon pump (IABP).MethodsA total of 100 AMI patients with IABP assistance due to hemodynamic instability at Wuhan Asia Heart Hospital were enrolled in the study....